1. Home
  2. SWX vs LYEL Comparison

SWX vs LYEL Comparison

Compare SWX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Gas Holdings Inc. (DE)

SWX

Southwest Gas Holdings Inc. (DE)

N/A

Current Price

$81.32

Market Cap

5.9B

Sector

Utilities

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$9.43

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SWX
LYEL
Founded
1931
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
320.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
SWX
LYEL
Price
$81.32
$9.43
Analyst Decision
Strong Buy
Buy
Analyst Count
9
8
Target Price
★ $101.75
$37.88
AVG Volume (30 Days)
★ 522.2K
105.0K
Earning Date
11-04-2026
11-11-2026
Dividend Yield
★ 3.16%
N/A
EPS Growth
★ 120.29
N/A
EPS
★ 2.49
N/A
Revenue
★ $5,433,972,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.46
N/A
P/E Ratio
$32.93
★ N/A
Revenue Growth
★ 9.56
N/A
52 Week Low
$76.74
$9.45
52 Week High
$94.47
$45.00

Technical Indicators

Market Signals
Indicator
SWX
LYEL
Relative Strength Index (RSI) 27.54 27.89
Support Level $78.37 N/A
Resistance Level $89.83 $15.38
Average True Range (ATR) 1.42 0.52
MACD -0.29 -0.09
Stochastic Oscillator 7.44 12.67

Price Performance

Historical Comparison
SWX
LYEL

About SWX Southwest Gas Holdings Inc. (DE)

Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: